Aljazira Capital

Aljazira Capital is the investment arm of Bank AlJazira, a Saudi Arabian Sharia-compliant bank, and operates more like a regional growth equity and asset-management platform than an early-stage VC. Stage focus is Series B and growth, check sizes sit in the $1M to $5M range as disclosed but the firm participates in larger syndicate rounds where institutional scale is needed, and healthcare interest spans digital health and care-delivery tech-enabled services, with AI not a stated focus. The right founder for Aljazira Capital is a maturing healthcare business with real revenue, GCC distribution, and a clear path to a Saudi or wider regional growth round, often as part of a syndicate alongside Saudi sovereign-aligned capital, regional family offices, and other PE-style investors. The wrong founder is an early-stage seed company; Aljazira does not lead small rounds, and pre-revenue diligence cycles will frustrate both sides. Intro paths run through Saudi institutional networks: investment bankers active in Riyadh and Jeddah, the PIF ecosystem, regional placement agents, and law firms such as Khoshaim and Associates or AlMadhi & Co. Existing portfolio CEOs and other GCC syndicate participants such as Riyad Capital, Jadwa, and SNB Capital are also natural connectors. Cold inbound rarely advances at this stage of capital. In the pitch, lead with audited or audit-ready financials, a clear use of proceeds tied to Saudi market expansion or a new product line, and explicit Sharia-compliance posture, since Aljazira’s bank parentage means structures that violate Sharia screens will not pass investment committee. Show a credible exit narrative tied to either Tadawul listing optionality or strategic acquirers operating in the GCC health sector. Be specific about the Health Sector Transformation Program and how regulatory tailwinds, mandatory health insurance expansion, or NPHIES interoperability rules create or constrain your business. Caveats include the slower diligence and committee process typical of bank-affiliated investors, and the reality that Sharia-compliance review can require structural changes including avoidance of conventional debt, certain insurance products, and any haram-adjacent revenue streams. Founders who arrive with a clean structure save weeks of rework. For the right growth-stage healthcare company, Aljazira is a credible Saudi institutional partner with the depth to participate in subsequent rounds and provide regional credibility; for the wrong company, it is the wrong stage and structure.